File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL

Conference Paper: Enhanced HIV-1 Gag-specific immunity induced by a sPD-1-based vaccine directed to dendritic cells

TitleEnhanced HIV-1 Gag-specific immunity induced by a sPD-1-based vaccine directed to dendritic cells
Authors
KeywordsMedical sciences
Allergology and immunology
Issue Date2011
PublisherAmerican Association of Immunologists. The Journal's web site is located at http://www.jimmunol.org
Citation
The 98th Annual Meeting of the America Association of Immunologists (AAI 2011), San Francisco, CA., 13-17 May 2011. In Journal of Immunology, 2011, v. 186 meeting abstract suppl., abstract no. 53.23 How to Cite?
AbstractHIV/AIDS is a serious disease worldwide. The development of a safe, effective and affordable HIV-1 vaccine remains the ultimate solution. This study is based on the discovery of a negative immune regulatory system, the PD-1/PD-L pathway, which exists on both human and other animals. The PD-1 ligands (PD-L1 and PD-L2) are expressed on DCs. So we hypothesize to utilize the soluble PD-1 parts to intervene in the negative signal transmission of the PD-1 pathway and to target the antigen to DCs as a mean to indentify vaccine strategy to enhance the virus specific immune responses. Here we constructed the novel vaccine and controls by inserting soluble PD-1 gene and/or HIV-1 p24 gene into the pVAX1 vector with fusing of rabbit Fc fragment named mspd1-p24-fc, and controls named mspd1-IgV -p24-fc and p24-fc. When compared with control vaccines, we discovered that mspd1-p24fc can significantly enhance HIV-1 Gag-specific immune responses by measuring the number of IFN- expressed CD4 and CD8 T cells using Elispot assays and CD8 T cell tetramer staining. Furthermore, the mspd1-p24-fc can significantly enhance humoral immune responses by anti-Gag antibody titer analysis. Importantly, this novel vaccine protects mice against recombinant vaccinia virus-gagpol challenges. This novel vaccine design may be used as DNA vaccine model against other infectious disease and cancer which need eliciting significant antigen specific humoral and cellular immune responses.
Persistent Identifierhttp://hdl.handle.net/10722/137934
ISSN
2015 Impact Factor: 4.985
2015 SCImago Journal Rankings: 3.549

 

DC FieldValueLanguage
dc.contributor.authorZhou, Jen_US
dc.contributor.authorWang, Hen_US
dc.contributor.authorTan, Zen_US
dc.contributor.authorDu, Yen_US
dc.contributor.authorChen, Zen_US
dc.date.accessioned2011-08-26T14:37:16Z-
dc.date.available2011-08-26T14:37:16Z-
dc.date.issued2011en_US
dc.identifier.citationThe 98th Annual Meeting of the America Association of Immunologists (AAI 2011), San Francisco, CA., 13-17 May 2011. In Journal of Immunology, 2011, v. 186 meeting abstract suppl., abstract no. 53.23en_US
dc.identifier.issn0022-1767-
dc.identifier.urihttp://hdl.handle.net/10722/137934-
dc.description.abstractHIV/AIDS is a serious disease worldwide. The development of a safe, effective and affordable HIV-1 vaccine remains the ultimate solution. This study is based on the discovery of a negative immune regulatory system, the PD-1/PD-L pathway, which exists on both human and other animals. The PD-1 ligands (PD-L1 and PD-L2) are expressed on DCs. So we hypothesize to utilize the soluble PD-1 parts to intervene in the negative signal transmission of the PD-1 pathway and to target the antigen to DCs as a mean to indentify vaccine strategy to enhance the virus specific immune responses. Here we constructed the novel vaccine and controls by inserting soluble PD-1 gene and/or HIV-1 p24 gene into the pVAX1 vector with fusing of rabbit Fc fragment named mspd1-p24-fc, and controls named mspd1-IgV -p24-fc and p24-fc. When compared with control vaccines, we discovered that mspd1-p24fc can significantly enhance HIV-1 Gag-specific immune responses by measuring the number of IFN- expressed CD4 and CD8 T cells using Elispot assays and CD8 T cell tetramer staining. Furthermore, the mspd1-p24-fc can significantly enhance humoral immune responses by anti-Gag antibody titer analysis. Importantly, this novel vaccine protects mice against recombinant vaccinia virus-gagpol challenges. This novel vaccine design may be used as DNA vaccine model against other infectious disease and cancer which need eliciting significant antigen specific humoral and cellular immune responses.-
dc.languageengen_US
dc.publisherAmerican Association of Immunologists. The Journal's web site is located at http://www.jimmunol.org-
dc.relation.ispartofJournal of Immunologyen_US
dc.subjectMedical sciences-
dc.subjectAllergology and immunology-
dc.titleEnhanced HIV-1 Gag-specific immunity induced by a sPD-1-based vaccine directed to dendritic cellsen_US
dc.typeConference_Paperen_US
dc.identifier.emailZhou, J: jingying@hku.hken_US
dc.identifier.emailWang, H: hbwang@hkucc.hku.hken_US
dc.identifier.emailTan, Z: zhiwutan@hku.hken_US
dc.identifier.emailDu, Y: biodu@hku.hken_US
dc.identifier.emailChen, Z: zchenai@hku.hk-
dc.identifier.authorityChen, Z=rp00243en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.hkuros190683en_US
dc.identifier.volume186-
dc.identifier.issuemeeting abstract suppl.-
dc.publisher.placeUnited States-
dc.description.otherThe 98th Annual Meeting of the America Association of Immunologists (AAI 2011), San Francisco, CA., 13-17 May 2011. In Journal of Immunology, 2011, v. 186 meeting abstract suppl., abstract no. 53.23-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats